Clinical Connection Home
  Welcome To
Clinical Connection
 
Be notified of new studies!
Tetanus Clinical Trials, Diagnosis, and Treatment
Thank you for your interest in clinical trials for Tetanus.

Please click "Search" to find Tetanus clinical trials and medical research studies or read below for information on Tetanus diagnosis and treatment.

If you receive too many study listings you may enter your zip code to find the locations closest to you.


Any Of These Words:
OR
All Of These Words
OR
This Exact Phrase:
AND
Zip Code:
Distance:
Your Search Returned No Results.
Search results will appear below.
Browse All Available Clinical Trials

Join Now to be Notified of New Clinical Trials

View Information and Clinical Trials for Other Conditions


Tetanus

Tetanus is a medical condition that is characterized by a prolonged contraction of skeletal muscle fibers. The primary symptoms are caused by tetanospasmin, a neurotoxin produced by the Gram-positive, obligate anaerobic bacterium Clostridium tetani. Infection generally occurs through wound contamination, and often involves a cut or deep puncture wound. As the infection progresses, muscle spasms in the jaw develop hence the common name, lockjaw. This is followed by difficulty swallowing and general muscle stiffness and spasms in other parts of the body. Infection can be prevented by proper immunization and by post-exposure prophylaxis.

The clinical manifestations of tetanus are caused when tetanus toxin blocks inhibitory nerve impulses, by interfering with the release of neurotransmitters. This leads to unopposed muscle contraction and spasm. Seizures may occur, and the autonomic nervous system may also be affected. The frequency of action potentials at the neuromuscular junctions increases above a threshold at which point muscle fibers enter a state of tetanus, a state of sustained maximal contraction. The term tetany refers to sustained muscle contraction that is not caused by tetanus.

Current Research

For current research articles click - here

Signs and Symptoms

Tetanus affects skeletal muscle, a type of striated muscle. The other type of striated muscle, cardiac or heart muscle cannot be tetanized because of their intrinsic electrical properties. In recent years, approximately 11% of reported tetanus cases have been fatal. The highest mortality rates are in unvaccinated persons and persons over 60 years of age. C. tetani, the bacteria that causes tetanus, is recovered from the initial wound in only about 30% of cases, and can be found in patients who do not have tetanus.

The incubation period of tetanus ranges from 3 to 21 days, with an average onset of clinical presentation of symptoms in 8 days. In general, the farther the injury site is from the central nervous system, the longer the incubation period. The shorter the incubation period, the higher the chance of death. In neonatal tetanus, symptoms usually appear from 4 to 14 days after birth, averaging about 7 days. On the basis of clinical findings, four different forms of tetanus have been described.

Local tetanus is an uncommon form of the disease, in which patients have persistent contraction of muscles in the same anatomic area as the injury. The contractions may persist for many weeks before gradually subsiding. Local tetanus is generally milder; only about 1% of cases are fatal, but it may precede the onset of generalized tetanus.

Cephalic tetanus is a rare form of the disease, occasionally occurring with otitis media (ear infections) in which C. tetani is present in the flora of the middle ear, or following injuries to the head. There is involvement of the cranial nerves, especially in the facial area.

Generalized tetanus is the most common type of tetanus, representing about 80% of cases. The generalized form usually presents with a descending pattern. The first sign is trismus or lockjaw, followed by stiffness of the neck, difficulty in swallowing, and rigidity of pectoral and calf muscles. Other symptoms include elevated temperature, sweating, elevated blood pressure, and episodic rapid heart rate. Spasms may occur frequently and last for several minutes. Spasms continue for 3–4 weeks and complete recovery may take months.

Neonatal tetanus is a form of generalized tetanus that occurs in newborn infants. It occurs in infants who have not acquired passive immunity because the mother has never been immunized. It usually occurs through infection of the unhealed umbilical stump, particularly when the stump is cut with a non-sterile instrument. Neonatal tetanus is common in many developing countries and is responsible for 14% (215,000) of all neonatal deaths, but is very rare in developed countries.

Spatula Test

The "spatula test" for tetanus involves touching the posterior pharyngeal wall with a sterile, soft-tipped instrument and observing the effect. A positive test result is the involuntary contraction of the jaw (biting down on the "spatula"), and a negative test result would normally be a gag reflex attempting to expel the foreign object.

A short report in The American Journal of Tropical Medicine and Hygiene purports that in a patient research study, the spatula test had a high specificity (zero false-positive test results) and a high sensitivity (94% of infected patients produced a positive test result).

Treatment

The wound must be cleaned. Dead and infected tissue should be removed by surgical debridement. Metronidazole treatment decreases the number of bacteria but has no effect on the bacterial toxin. Penicillin was once used to treat tetanus, but is no longer the treatment of choice because of a theoretical risk of increased spasms. It should still be used if metronidazole is not available. Passive immunization with human anti-tetanospasmin immunoglobulin or tetanus immune globulin is crucial. If specific anti-tetanospasmin immunoglobulin is not available, then normal human immunoglobulin may be given instead. All tetanus victims should be vaccinated against the disease or offered a booster shot.

It takes 2-14 days for symptoms to develop after infection. Symptoms peak 17 days after infection.

Mild Tetanus

Mild cases of tetanus can be treated with:
  • Tetanus immune globulin IV or IM
  • Metronidazole IV for 10 days
  • Diazepam
  • Tetanus vaccination

Severe Tetanus

Severe cases will require admission to intensive care. In addition to the measures listed above for mild tetanus:
  • Human tetanus immunoglobulin injected intrathecally (increases clinical improvement from 4% to 35%)
  • Tracheostomy and mechanical ventilation for 3 to 4 weeks,
  • Magnesium, as an intravenous (IV) infusion, to prevent muscle spasm,
  • Diazepam (known under the common name Valium) as a continuous IV infusion,
  • The autonomic effects of tetanus can be difficult to manage (alternating hyper- and hypotension, hyperpyrexia/hypothermia) and may require IV labetalol, magnesium, clonidine, or nifedipine.
Drugs such as chlorpromazine or diazepam, or other muscle relaxants can be given to control the muscle spasms. In extreme cases it may be necessary to chemically paralyze the patient with curare-like drugs and use a mechanical ventilator. In order to survive a tetanus infection, the maintenance of an airway and proper nutrition are required. An intake of 3500-4000 Calories, and at least 150g of protein, is often given in liquid form through a tube directly into the stomach, or through a drip into a vein. This high-caloric diet maintenance is required due to the increased metabolic strain brought on by the increased muscle activity.

Prevention

Tetanus can be prevented by vaccination.[5] The CDC recommends that adults receive a booster vaccine every ten years, and standard care in many places is to give the booster to any patient with a puncture wound who is uncertain of when he or she was last vaccinated, or if the patient has had fewer than 3 lifetime doses of the vaccine. The booster cannot prevent a potentially fatal case of tetanus from the current wound, as it can take up to two weeks for tetanus antibodies to form. In children under the age of seven, the tetanus vaccine is often administered as a combined vaccine, DPT vaccine or DTaP, which also includes vaccines against diphtheria and pertussis. For adults and children over seven, the Td vaccine (tetanus and diphtheria) or Tdap (tetanus, diphtheria, and acellular pertussis) is commonly used.

Epidemiology

Tetanus is a global health problem since C. tetani and Geravium tetani spores are ubiquitous. The disease occurs almost exclusively in persons who are unvaccinated or inadequately immunized. Tetanus occurs worldwide but is more common in hot, damp climates with soil rich in organic matter. This is particularly true with manure-treated soils, the spores are widely distributed in the intestines and feces of many non-human animals such as horses, sheep, cattle, dogs, cats, rats, guinea pigs, and chickens. In agricultural areas, a significant number of human adults may harbor the organism. The spores can also be found on skin surfaces and in contaminated heroin.

Tetanus, particularly the neonatal form, remains a significant public health problem in non-industrialized countries. There are about one million cases of tetanus reported worldwide, causing an estimated 300,000 to 500,000 deaths each year.

In the US, there are fewer than 100 cases and approximately five deaths each year. Nearly all of the cases in the US occur in unimmunized individuals or individuals who have allowed their inoculations to lapse, whereas most cases in developing countries are due to the neonatal form of tetanus.

Tetanus is not contagious from person to person and is the only vaccine-preventable disease that is infectious but is not contagious.

Association with Rust

Tetanus is often associated with rust, especially rusty nails, but this concept is somewhat misleading. Objects that accumulate rust are often found outdoors, or in places that harbor anaerobic bacteria, but the rust itself does not cause tetanus nor does it contain more C. tetani bacteria. The rough surface of rusty metal merely provides a prime habitat for a C. tetani endospore to reside. An endospore is a non-metabolising survival structure that begins to metabolise and cause infection once in an adequate environment. Because C. tetani is an anaerobic bacterium, it, and its endospores, will thrive in an environment that lacks oxygen. Hence, stepping on a nail (rusty or not) may result in a tetanus infection, due to the ideal bacterial breeding ground provided by the low-oxygen environment of a puncture wound.

Famous Tetanus Victims

  • George Montagu - English ornithologist; contracted tetanus when he stepped on a nail.
  • Joe Powell - English footballer; contracted following amputation of a badly broken arm.
  • John A. Roebling - Civil Engineer and Architect famous for his bridge designs, particularly the Brooklyn Bridge; contracted following amputation of his foot due to an injury caused by a ferry when it crashed into a wharf.
  • George Crockett Strong - Union brigadier general in the American Civil War; from wounds sustained in the assault against Fort Wagner on Morris Island, South Carolina.
  • Fred Thomson - silent film actor; stepped on a nail.
  • Johann Tserclaes, Count of Tilly; wounded by a cannon ball in the Battle of Rain.
  • Traveller - General Robert E. Lee's favorite horse; stepped on a nail.
  • John Thoreau; brother of Henry David Thoreau



(adapted from Wikipedia, the free encyclopedia http://en.wikipedia.org/wiki/tetanus)





Findings From Current Research

Maternal and Neonatal Tetanus

Authors: Roper MH, Vandelaer JH, Gasse FL.

Weybridge, VT, USA.

Maternal and neonatal tetanus are important causes of maternal and neonatal mortality, claiming about 180 000 lives worldwide every year, almost exclusively in developing countries. Although easily prevented by maternal immunisation with tetanus toxoid vaccine, and aseptic obstetric and postnatal umbilical-cord care practices, maternal and neonatal tetanus persist as public-health problems in 48 countries, mainly in Asia and Africa. Survival of tetanus patients has improved substantially for those treated in hospitals with modern intensive-care facilities; however, such facilities are often unavailable where the tetanus burden is highest. The Maternal and Neonatal Tetanus Elimination Initiative assists countries in which maternal and neonatal tetanus has not been eliminated to provide immunisation with tetanus toxoid to women of childbearing age. The ultimate goal of this initiative is the worldwide elimination of maternal and neonatal tetanus. Since tetanus spores cannot be removed from the environment, sustaining elimination will require improvements to presently inadequate immunisation and health-service infrastructures, and universal access to those services. The renewed worldwide commitment to the reduction of maternal and child mortality, if translated into effective action, could help to provide the systemic changes needed for long-term elimination of maternal and neonatal tetanus.

Journal: Lancet. 2007 Sep 11
Adapted from PubMed; click here to access full journal article.




New Combined Tetanus-Diptheria-Acellular Pertussis Vaccines for Adults: Primary Care Physician Attitudes and Preferences

Authors: Davis MM, Kretsinger K, Cowan AE, Stokley S, Clark SJ.

Child Health Evaluation and Research Unit, Division of General Pediatrics, University of Michigan, Ann Arbor, Michigan 48109-0456, USA. mattdav@med.umich.edu

Availability of combined tetanus-diphtheria-acellular pertussis (Tdap) vaccines for adults offers a new pertussis prevention strategy for the US. Successful uptake of Tdap vaccine will depend partly on the attitudes and practices of primary care physicians, including their experience with Td boosters. We conducted a mail survey in August 2005 of a national random sample of 399 family physicians (FPs) and 399 general internists (IMs) to assess practices related to Td boosters, clinical experience with pertussis, and attitudes toward a potential Tdap vaccine recommendation for adults. The response rate was 49% (52% FPs, 46% IMs). Among 336 eligible respondents, half reported having clinical experience with pertussis. Most (81%) would recommend Tdap vaccine for their adult patients, and 73% support targeting adults likely to come in close contact with infants. Attitudes toward a potential Tdap vaccine recommendation differed by whether providers stock and administer Td boosters. We conclude that adult primary care providers in the US are likely to recommend Tdap vaccine to their adult patients, in concordance with recent national recommendations. Future research should assess the extent to which barriers impede adoption of Tdap vaccine recommendations.

Journal: Hum Vaccin. 2007 Jul-Aug;3(4):130-4. Epub 2007 Apr 8.
Adapted from PubMed; click here to access full journal article.




Audit of Tetanus Prevention Knowledge and Practices in Accident and Emergency Departments in England

Authors: Savage EJ, Nash S, McGuinness A, Crowcroft NS.

Immunisation Department, Centre for Infections, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, UK. emma.savage@hpa.org.uk

OBJECTIVES: To assess the knowledge and current tetanus prevention practices of various staff members in accident and emergency (A&E) departments. DESIGN, SETTING AND PARTICIPANTS: A structured questionnaire containing 16 questions on tetanus guidance, anti-tetanus practice, vaccination preparations and information on the population served by the department was sent to medical and nursing staff in A&E departments across England. RESULTS: 366 completed questionnaires from 67 hospitals were returned. 48.9% of the questionnaires were completed by the medical staff and 39.9% by the nursing staff at various grades. 75% of respondents said that their department had a local tetanus guideline, but only 29% stated that the tetanus guidelines were always followed. 31.4% of respondents said that injecting drug users were managed as a high-risk group in their department. Many respondents did not follow the national policy; they tended to err on the side of caution when it came to defining and treating tetanus-prone wounds, with 22.1% stating that they would consider any wound tetanus prone. Contrary to current Department of Health guidelines, 46.2% of respondents said that they would give a booster dose if the fifth dose had been given >10 years ago. CONCLUSIONS: There are clear differences between the recommended guidelines for tetanus prevention and current practice in A&E departments. The changes announced in 2002 do not seem to have been widely implemented. As a result, the apparent success of the national tetanus vaccination programme may be the result of more cautious clinical practice than would be expected from the UK policy. If national recommendations for tetanus are implemented in clinical practice, then the impact on control of the disease should be monitored closely.

Journal: Emerg Med J. 2007 Jun;24(6):417-21.
Adapted from PubMed; click here to access full journal article.




Attitudes of US Obstetricians Toward a Combined Tetanus-Diphtheria-Acellular Pertussis Vaccine for Adults

Authors: Clark SJ, Adolphe S, Davis MM, Cowan AE, Kretsinger K.

Child Health Evaluation and Research Unit, University of Michigan, Ann Arbor, MI 48109, USA.

OBJECTIVE: To describe obstetricians' perspectives related to tetanus-diphtheria-acellular pertussis (Tdap) vaccination of mothers and other adults in close contact with infants. METHODS: Mail survey of national random sample of 400 obstetricians. RESULTS: Response rate was 54%. Most respondents would likely recommend Tdap for women during the postpartum hospital stay (78%) or during pregnancy (69%) if a national recommendation was issued. Expected barriers were knowing the date of patients' most recent Td booster (74%) and patient resistance (46%). Most felt that obstetricians have a role in promoting and administering Tdap vaccine to adults other than mothers likely to come in close contact with infants. CONCLUSION: Obstetricians are likely to agree with the recent provisional US recommendation to administer Tdap to postpartum mothers and other adults expected to come in close contact with infants. Obstetricians would also be likely to support a potential recommendation to administer Tdap during pregnancy. Barriers to adoption of new Tdap vaccine recommendations should be monitored.

Journal: Infect Dis Obstet Gynecol. 2006;2006:87040.
Adapted from PubMed; click here to access full journal article.




Join Now - Become a free member and get notified about studies in your area when they become available.

Browse Our Current Studies - Look over all of our current studies being conducted throughout the United States.

View Information and Clinical Trials for Other Conditions - Access all of our health-related content.
Hypertension (High Blood Pressure) - Sacramento CA
in Carmichael, CA


Bipolar Depression - Norristown PA
in Norristown, PA


Depression - Norristown PA
in Norristown, PA


Major Depression - New York NY
in New York, NY


Bipolar Depression - New York NY
in New York, NY


Generalized Anxiety Disorder - New York NY
in New York, NY


Are You Ready to Quit Smoking? - Menlo Park CA
in Menlo Park, CA


Psoriasis - Baltimore MD
in Baltimore, MD


Eczema (Atopic Dermatitis) - NATIONWIDE
in NATIONWIDE,


Genital Warts - NATIONWIDE
in NATIONWIDE,


Diabetic Neuropathy - DeLand FL
in DeLand, FL


Healthy Volunteers (Sleep Disorders) - DeLand FL
in DeLand, FL


ADHD in Children and Adolescents - NATIONWIDE
in NATIONWIDE,


B-Cell Lymphom - NATIONWIDE
in NATIONWIDE,


Brain Tumors and Brain Cancers - NATIONWIDE
in NATIONWIDE,


 


© 1998-2008 Clinical Trials Home | Links | Terms And Conditions | Sitemap | Suggestion/Feedback
All trademarks are property of their legal owners. | All Rights Reserved

ClinicalConnection.com is a resource that provides individuals with information regarding clinical trials that are being conducted nationwide.
ClinicalConnection.com does not conduct these clinical trials nor endorse them. Please consult your doctor or physician before participating.